A comparative review of laboratory-developed tests utilizing Invader® HPV analyte-specific reagents for the detection of high-risk human papillomavirus

Journal of Clinical Virology

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Stillman, Michael J ^a   Day, Stephen P ^a   Schutzbank, Ted E ^b  

^a HOLOGIC INC   (United States)

^b Labcorp Drug Development   (United States)

Author keywords

Cervical cancer screening; High risk human papillomavirus (HPV) detection; HPV testing; Invader chemistry Analyte specific reagents

Indexed keywords

ANALYTIC METHOD; ARTICLE; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LABORATORY TEST; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VALIDATION STUDY; VIRUS DETECTION; WART VIRUS;

DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VIROLOGY;

EID: 67949099183     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70011-3     Document Type: Article

References (26)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0 (2004), IARC Press, Lyon
2. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
4. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
5. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European guidelines for quality assurance in cervical cancer screening. 2nd ed. (2008), Office for Official Publications of the European Communities, Luxembourg
6. Deloukas P., and Bentley D. The HapMap project and its application to genetic studies of drug response. Pharmacogenomics J 4 (2004) 88-90
7. de Arruda M., Lyamichev V.I., Eis P.S., Iszczyszyn W., Kwiatkowski R.W., Law S.M., et al. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev Mol Diagn 2 (2002) 487-496
8. Karlsen F., Kalantari M., Jenkins A., Pettersen E., Kristensen G., Holm R., et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34 (1996) 2095-2100
9. Morris B.J. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med 43 (2005) 1171-1177
10. Day S.P., Hudson A., Mast A., Sander T., Curtis M., Olson S., Chehak L., Quigley N., Ledfordt J., Yen-Lieberman B., Kohn D., Quigley D.I., and Olson M. Analytical performance of the Investigational Use Only Cervista™ HPV HR test as determined by a multi-center study. J Clin Virol 45 Suppl 1 (2009) S63-S72
11. Poljak M., Marin I.J., Seme K., and Vince A. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25 (2002) S89-S97
12. Johnson L.R., Starkey C.R., Palmer J., Taylor J., Stout S., Holt S., et al. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol 130 (2008) 401-408
13. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
14. Seme K., Fujs K., Kocjan B.J., and Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods 134 (2006) 252-256
15. Ginocchio C.C., Barth D., and Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J Clin Microbiol 46 (2008) 1641-1646
16. Schutzbank T.E., Jarvis C., Kahmann N., Lopez K., Weimer M., and Yount A. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J Clin Microbiol 45 (2007) 4067-4069
17. Wong A.K., Chan R.C., Nichols W.S., and Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J Clin Microbiol 46 (2008) 869-875
18. Hybrid Capture® 2 High-Risk HPV DNA Test® [package insert] (2007), Digene Corporation, Gaithersburg, MD, USA
19. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 6 (2005) 204
20. Stoler M.H., Castle P.E., Solomon D., and Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 127 (2007) 335-337
21. Solomon D., Schiffman M., and Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93 (2001) 293-299
22. Evans M.F., Adamson C.S., Papillo J.L., St John T.L., Leiman G., and Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 106 (2006) 1054-1064
23. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
24. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
25. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
26. Wong A.K., Chan R.C., Nichols W.S., and Bose S. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. Cancer 115 (2009) 823-832